person · Reporting owner
Schreiber Christopher C
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Q/C TECHNOLOGIES, INC.MYMD · Entity 7735 | Director | June 07, 2023 | June 09, 2023 |
| Sono Group N.V.SEVCF · Entity 1306 | Director | January 01, 2025 | January 02, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Q/C TECHNOLOGIES, INC.
Report date June 07, 2023 · Filed June 09, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.66 · Expires 2028-06-07 | Direct | 150,000 |
Reported balance
After 2023-06-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-07 · Grant · Acquired 150,000 · Balance 150,000 F1: The stock options vest as follows: (i) one third on the date of grant; (ii) one third on the first anniversary of the date of grant; and (iii) one third on the second anniversary of the date of grant, provided that the Reporting Person remains employed by MyMD Pharmaceuticals, Inc. or a subsidiary on the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options vest as follows: (i) one third on the date of grant; (ii) one third on the first anniversary of the date of grant; and (iii) one third on the second anniversary of the date of grant, provided that the Reporting Person remains employed by MyMD Pharmaceuticals, Inc. or a subsidiary on the applicable vesting date.
Sono Group N.V.
Report date January 01, 2025 · Filed January 02, 2025
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 07, 2023 Filed Jun 9, 2023 22:00 UTC | Q/C TECHNOLOGIES, INC. MYMD · Entity 7735 | GrantEmployee Stock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $1.66 | $0.00 |
DisclosureSEC source: 0001493152-23-020796 · ownership.xml · derivative · entry 1 Schreiber Christopher C · CIK 0001750076 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2028-06-07 F1 · derivative.exercise_date: The stock options vest as follows: (i) one third on the date of grant; (ii) one third on the first anniversary of the date of grant; and (iii) one third on the second anniversary of the date of grant, provided that the Reporting Person remains employed by MyMD Pharmaceuticals, Inc. or a subsidiary on the applicable vesting date. Read SEC document |
| October 14, 2021 Filed Oct 15, 2021 21:22 UTC | Q/C TECHNOLOGIES, INC. MYMD · Entity 7735 | GrantRestricted Stock Units · Derivative | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-025609 · ownership.xml · derivative · entry 1 Schreiber Christopher C · CIK 0001750076 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of MyMD Pharmaceuticals, Inc. (the "Company"). F2 · derivative.exercise_date: The RSUs vest as follows: (i) 33% if the Company's market capitalization equals or exceeds $500,000,000 for at least 10 trading days during any 20 consecutive trading day period ending on or after December 15, 2021 (the "Required Period") and the fair market value (the "FMV") of the common stock equals or exceeds $5.00, subject to standard adjustments (the "Minimum Share Value") during such Required Period, (ii) 33% if the Company's market capitalization equals or exceeds $750,000,000 for the Required Period at the Minimum Share Value, and (iii) the remainder if the Company's market capitalization equals or exceeds $1,000,000,000 for the Required Period at the Minimum Share Value; provided that the RSUs shall vest immediately upon the occurrence of a change in control that values the Company's common stock at least $500,000,000, provided that the Reporting Person is providing services to the Company on the closing date of such change in control. F2 · derivative.expiration_date: The RSUs vest as follows: (i) 33% if the Company's market capitalization equals or exceeds $500,000,000 for at least 10 trading days during any 20 consecutive trading day period ending on or after December 15, 2021 (the "Required Period") and the fair market value (the "FMV") of the common stock equals or exceeds $5.00, subject to standard adjustments (the "Minimum Share Value") during such Required Period, (ii) 33% if the Company's market capitalization equals or exceeds $750,000,000 for the Required Period at the Minimum Share Value, and (iii) the remainder if the Company's market capitalization equals or exceeds $1,000,000,000 for the Required Period at the Minimum Share Value; provided that the RSUs shall vest immediately upon the occurrence of a change in control that values the Company's common stock at least $500,000,000, provided that the Reporting Person is providing services to the Company on the closing date of such change in control. Read SEC document |
| April 16, 2021 Filed Apr 21, 2021 21:55 UTC | Q/C TECHNOLOGIES, INC. MYMD · Entity 7735 | Exercise / conversionRestricted Stock Units · Derivative | 131,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-009398 · ownership.xml · derivative · entry 3 Schreiber Christopher C · CIK 0001750076 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 131,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of MyMD Pharmaceuticals, Inc. (the "Company"). F3 · derivative.exercise_date: On September 11, 2020, the reporting person was granted 131,750 RSUs of the Company, which vested on April 16, 2021, upon the occurrence of a change in control. F3 · derivative.expiration_date: On September 11, 2020, the reporting person was granted 131,750 RSUs of the Company, which vested on April 16, 2021, upon the occurrence of a change in control. Read SEC document |
| April 16, 2021 Filed Apr 21, 2021 21:55 UTC | Q/C TECHNOLOGIES, INC. MYMD · Entity 7735 | Tax withholdingCommon Stock | 46,113 | $4.94 | $227,798.22 |
DisclosureSEC source: 0001493152-21-009398 · ownership.xml · nonDerivative · entry 2 Schreiber Christopher C · CIK 0001750076 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,238 F2 · shares: Represents 46,113 shares of RSUs withheld to pay the reporting person's tax withholding obligations incurred in connection with the vesting of 131,750 shares of RSUs on April 16, 2021. Read SEC document |
| April 16, 2021 Filed Apr 21, 2021 21:55 UTC | Q/C TECHNOLOGIES, INC. MYMD · Entity 7735 | Exercise / conversionCommon Stock | 131,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-21-009398 · ownership.xml · nonDerivative · entry 1 Schreiber Christopher C · CIK 0001750076 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of MyMD Pharmaceuticals, Inc. (the "Company"). F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of MyMD Pharmaceuticals, Inc. (the "Company"). Read SEC document |
| September 11, 2020 Filed Sep 11, 2020 22:22 UTC | Q/C TECHNOLOGIES, INC. AKER · Entity 7735 | GrantRestricted Stock Unit · Derivative | 263,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-017668 · ownership.xml · derivative · entry 1 Schreiber Christopher C · CIK 0001750076 · Director · Exec. Chairman and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,500 Underlying: Common Stock · 263,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of Akers Biosciences, Inc. (the "Company"). The Company may also elect to settle the vested RSUs for cash at its discretion. F2 · derivative.exercise_date: Reporting Person was granted 263,500 RSUs under the Company's 2018 Equity Incentive Plan, as amended (the "Plan"), with fifty percent (50%) of the RSUs to vest on the first anniversary of the date of grant, and the remaining fifty percent (50%) to vest on the second anniversary of the date of grant; provided that the RSUs shall vest immediately upon the occurrence of (i) a change in control, provided that the Reporting Person is employed by or providing services to the Company and its affiliates on the closing date of such change in control, (ii) the Reporting Person's termination of employment or service from the Company and its affiliates by reason of the Reporting Person's death or disability, or (iii) the Reporting Person's termination of employment or service by the Company without cause. F2 · derivative.expiration_date: Reporting Person was granted 263,500 RSUs under the Company's 2018 Equity Incentive Plan, as amended (the "Plan"), with fifty percent (50%) of the RSUs to vest on the first anniversary of the date of grant, and the remaining fifty percent (50%) to vest on the second anniversary of the date of grant; provided that the RSUs shall vest immediately upon the occurrence of (i) a change in control, provided that the Reporting Person is employed by or providing services to the Company and its affiliates on the closing date of such change in control, (ii) the Reporting Person's termination of employment or service from the Company and its affiliates by reason of the Reporting Person's death or disability, or (iii) the Reporting Person's termination of employment or service by the Company without cause. Read SEC document |
| January 01, 2020 Filed Jan 4, 2020 00:11 UTC | Q/C TECHNOLOGIES, INC. AKER · Entity 7735 | Exercise / conversionRestricted Stock Units · Derivative | 5,201 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-000166 · ownership.xml · derivative · entry 2 Schreiber Christopher C · CIK 0001750076 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,201 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of Akers Biosciences, Inc. (the "Company"). F2 · derivative.exercise_date: On March 29, 2019, the reporting person was granted 5,201 RSUs of the Company, which vested on January 1, 2020. F2 · derivative.expiration_date: On March 29, 2019, the reporting person was granted 5,201 RSUs of the Company, which vested on January 1, 2020. Read SEC document |
| January 01, 2020 Filed Jan 4, 2020 00:11 UTC | Q/C TECHNOLOGIES, INC. AKER · Entity 7735 | Exercise / conversionCommon Stock | 5,201 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-20-000166 · ownership.xml · nonDerivative · entry 1 Schreiber Christopher C · CIK 0001750076 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,201 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of Akers Biosciences, Inc. (the "Company"). Read SEC document |
| March 29, 2019 Filed Apr 2, 2019 21:15 UTC | Q/C TECHNOLOGIES, INC. AKER · Entity 7735 | GrantRestricted Stock Units · Derivative | 124,827 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-19-004746 · ownership.xml · derivative · entry 1 Schreiber Christopher C · CIK 0001750076 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,827 Underlying: Common Stock · 124,827 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of Akers Biosciences, Inc. (the "Company"). The Company may also elect to settle the vested RSUs for cash at its discretion. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of Akers Biosciences, Inc. (the "Company"). The Company may also elect to settle the vested RSUs for cash at its discretion. F2 · derivative.exercise_date: Reporting Person was granted 124,827 RSUs under the Company's 2018 Equity Incentive Plan, as amended (the "Plan"), each of which shall vest on January 1, 2020; provided that the RSUs shall vest immediately upon a Change in Control. All capitalized but undefined terms have the meanings ascribed thereto by the Plan. F2 · derivative.expiration_date: Reporting Person was granted 124,827 RSUs under the Company's 2018 Equity Incentive Plan, as amended (the "Plan"), each of which shall vest on January 1, 2020; provided that the RSUs shall vest immediately upon a Change in Control. All capitalized but undefined terms have the meanings ascribed thereto by the Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.